Co-treatment with retinyl retinoate and a PPARα agonist reduces retinoid dermatitis

Bora Kim, Jin E. Kim, Hyuk Kim, Joo D. Lee, Kang Yell Choi, Seung H. Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Retinoids have been used for the treatment of skin disorders such as acne, psoriasis, and photoaging. However, despite their beneficial effects, topical retinoids often cause severe local irritation called retinoid dermatitis. We previously developed a novel vitamin A derivative, retinyl retinoate, which induces less irritation and affords excellent tolerance. In this study, we examined whether co-treatment with topical peroxisome proliferator-activated receptor-α (PPARα) agonists (e.g. WY14643) reduce retinoid dermatitis in hairless mouse skin. Methods The effect of concomitant treatment with a PPARα agonist on retinoid dermatitis in hairless mouse epidermis was evaluated by measuring transepidermal water loss, epidermal histology, and cytokine expression. Results Retinyl retinoate induced less severe retinoid dermatitis than retinoic acid. Topical application of a PPARα agonist improved the stratum corneum structure and function, reduced mRNA expression of interleukin (IL)-1α, tumor necrosis factor-α and IL-8, and inhibited ear edema induced by retinoic acid or retinyl retinoate. Conclusions Our results indicate that PPARα agonists can potentially be used to improve retinoid dermatitis. We suggest that co-treatment with retinyl retinoate and a PPARα agonist may reduce or prevent detrimental alterations in retinoid-treated skin.

Original languageEnglish
Pages (from-to)733-741
Number of pages9
JournalInternational Journal of Dermatology
Volume51
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Peroxisome Proliferator-Activated Receptors
Retinoids
Dermatitis
Hairless Mouse
Therapeutics
Tretinoin
Skin
retinyl retinoate
Acne Vulgaris
Vitamin A
Interleukin-8
Interleukin-1
Psoriasis
Epidermis
Cornea
Ear
Edema
Histology
Tumor Necrosis Factor-alpha
Cytokines

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Kim, Bora ; Kim, Jin E. ; Kim, Hyuk ; Lee, Joo D. ; Choi, Kang Yell ; Lee, Seung H. / Co-treatment with retinyl retinoate and a PPARα agonist reduces retinoid dermatitis. In: International Journal of Dermatology. 2012 ; Vol. 51, No. 6. pp. 733-741.
@article{047866802ea5466199741ac56a723007,
title = "Co-treatment with retinyl retinoate and a PPARα agonist reduces retinoid dermatitis",
abstract = "Background Retinoids have been used for the treatment of skin disorders such as acne, psoriasis, and photoaging. However, despite their beneficial effects, topical retinoids often cause severe local irritation called retinoid dermatitis. We previously developed a novel vitamin A derivative, retinyl retinoate, which induces less irritation and affords excellent tolerance. In this study, we examined whether co-treatment with topical peroxisome proliferator-activated receptor-α (PPARα) agonists (e.g. WY14643) reduce retinoid dermatitis in hairless mouse skin. Methods The effect of concomitant treatment with a PPARα agonist on retinoid dermatitis in hairless mouse epidermis was evaluated by measuring transepidermal water loss, epidermal histology, and cytokine expression. Results Retinyl retinoate induced less severe retinoid dermatitis than retinoic acid. Topical application of a PPARα agonist improved the stratum corneum structure and function, reduced mRNA expression of interleukin (IL)-1α, tumor necrosis factor-α and IL-8, and inhibited ear edema induced by retinoic acid or retinyl retinoate. Conclusions Our results indicate that PPARα agonists can potentially be used to improve retinoid dermatitis. We suggest that co-treatment with retinyl retinoate and a PPARα agonist may reduce or prevent detrimental alterations in retinoid-treated skin.",
author = "Bora Kim and Kim, {Jin E.} and Hyuk Kim and Lee, {Joo D.} and Choi, {Kang Yell} and Lee, {Seung H.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1111/j.1365-4632.2011.05332.x",
language = "English",
volume = "51",
pages = "733--741",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "6",

}

Co-treatment with retinyl retinoate and a PPARα agonist reduces retinoid dermatitis. / Kim, Bora; Kim, Jin E.; Kim, Hyuk; Lee, Joo D.; Choi, Kang Yell; Lee, Seung H.

In: International Journal of Dermatology, Vol. 51, No. 6, 01.06.2012, p. 733-741.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Co-treatment with retinyl retinoate and a PPARα agonist reduces retinoid dermatitis

AU - Kim, Bora

AU - Kim, Jin E.

AU - Kim, Hyuk

AU - Lee, Joo D.

AU - Choi, Kang Yell

AU - Lee, Seung H.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background Retinoids have been used for the treatment of skin disorders such as acne, psoriasis, and photoaging. However, despite their beneficial effects, topical retinoids often cause severe local irritation called retinoid dermatitis. We previously developed a novel vitamin A derivative, retinyl retinoate, which induces less irritation and affords excellent tolerance. In this study, we examined whether co-treatment with topical peroxisome proliferator-activated receptor-α (PPARα) agonists (e.g. WY14643) reduce retinoid dermatitis in hairless mouse skin. Methods The effect of concomitant treatment with a PPARα agonist on retinoid dermatitis in hairless mouse epidermis was evaluated by measuring transepidermal water loss, epidermal histology, and cytokine expression. Results Retinyl retinoate induced less severe retinoid dermatitis than retinoic acid. Topical application of a PPARα agonist improved the stratum corneum structure and function, reduced mRNA expression of interleukin (IL)-1α, tumor necrosis factor-α and IL-8, and inhibited ear edema induced by retinoic acid or retinyl retinoate. Conclusions Our results indicate that PPARα agonists can potentially be used to improve retinoid dermatitis. We suggest that co-treatment with retinyl retinoate and a PPARα agonist may reduce or prevent detrimental alterations in retinoid-treated skin.

AB - Background Retinoids have been used for the treatment of skin disorders such as acne, psoriasis, and photoaging. However, despite their beneficial effects, topical retinoids often cause severe local irritation called retinoid dermatitis. We previously developed a novel vitamin A derivative, retinyl retinoate, which induces less irritation and affords excellent tolerance. In this study, we examined whether co-treatment with topical peroxisome proliferator-activated receptor-α (PPARα) agonists (e.g. WY14643) reduce retinoid dermatitis in hairless mouse skin. Methods The effect of concomitant treatment with a PPARα agonist on retinoid dermatitis in hairless mouse epidermis was evaluated by measuring transepidermal water loss, epidermal histology, and cytokine expression. Results Retinyl retinoate induced less severe retinoid dermatitis than retinoic acid. Topical application of a PPARα agonist improved the stratum corneum structure and function, reduced mRNA expression of interleukin (IL)-1α, tumor necrosis factor-α and IL-8, and inhibited ear edema induced by retinoic acid or retinyl retinoate. Conclusions Our results indicate that PPARα agonists can potentially be used to improve retinoid dermatitis. We suggest that co-treatment with retinyl retinoate and a PPARα agonist may reduce or prevent detrimental alterations in retinoid-treated skin.

UR - http://www.scopus.com/inward/record.url?scp=84861311399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861311399&partnerID=8YFLogxK

U2 - 10.1111/j.1365-4632.2011.05332.x

DO - 10.1111/j.1365-4632.2011.05332.x

M3 - Article

C2 - 22607296

AN - SCOPUS:84861311399

VL - 51

SP - 733

EP - 741

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 6

ER -